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E-mail address: liu_jinsong@gibh.ac.cn (J. Liu).Human glucokinase (GK) plays an important role in glucose homeostasis. An E339K mutation in GK
was recently found to be associated with hyperglycemia. It showed lower enzyme activity and
impaired protein stability compared to the wild-type enzyme. Here, we present the crystal structure
of E339K GK in complex with glucose. This mutation results in a conformational change of His416,
spatially interfering with adenosine-triphosphate (ATP) binding. Furthermore, Ser411 at the ATP
binding site is phosphorylated and then hydrogen bonded with Thr82, physically blocking the
ATP binding. These ﬁndings provide structural basis for the reduced activity of this mutant.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction tus caused by mutations in an autosomal dominant gene. A num-Human glucokinase (GK) (adenosine-triphosphate (ATP): D-
glucose 6-phosphotransferase, EC 2.7.1.2) is a 52 kD enzyme that
can phosphorylate glucose to glucose-6-phosphate. It is mainly ex-
pressed in liver, pancreas, gut and brain [1,2]. Also known as hexo-
kinase IV or D, GK is a member of the hexokinase family that
catalyzes the ﬁrst step in glycolysis, playing a crucial role in glu-
cose homeostasis. However, GK exhibits sigmoidal kinetics instead
of the Michaelis–Menten kinetics of non-allosteric hexokinases [3].
It is also different from non-allosteric hexokinases in its lack of
product inhibition and relatively lower glucose afﬁnity. In pancre-
atic b-cells, GK functions as a glucose sensor [4]. In liver, it regu-
lates glucose uptake and storage [5]. Given its key role in glucose
homeostasis, mutations of the GK gene have profound inﬂuence
on its functions in human cells. To date, about 600 mutations have
been reported for the GK gene, including non-sense, missense, and
frameshift mutations [6,7]. A large number of GK mutations are
inactivating mutations associated with maturity-onset diabetes
of the young, type2 (MODY2). MODY2 is a form of diabetes melli-chemical Societies. Published by E
ylyl-imidodiphosphate; SEP,
; IPTG, isopropyl-b-D-thioga-
yethyl) phosphine; G6PDH,
amide adenine dinucleotideber of GK mutations, such as T51I, W99R, Y214C, V455M and
A456V, are activating mutations that result in persistent hyperins-
ulinemic hypoglycemia of infancy (PHHI) [8–11].
In 2004, Katama and colleagues determined the crystal struc-
tures of human GK in both active and inactive forms [12]. Their
results showed that GK has a small domain and a large domain sep-
arated by a deep cleft and undergoes a large conformational change
by the rotation of the small domain induced by glucose binding.
Their structure provides a general explanation of how the enzyme
activity of GK can be affected by some of the mutations, especially
those located in the glucose and ATP binding pockets and those
involved in the conformation transition. Recently, a new inactivat-
ing mutation E339K was found by Shen et al. in a Chinese family
with hyperglycemia [13]. This E339Kmutation, however, is situated
far from the ATP binding site. To understand how this mutation
affects GK activity, we determined the crystal structure of E339K
mutated GK. This ﬁrst mutated GK crystal structure will shed light
on how themutation causes the enzyme kinetic alterations andwill
provide a better understanding on how the enzyme works.
2. Materials and methods
2.1. Protein expression and puriﬁcation
The E339K GK, with an N-terminal MGHHHHHHENLYFQGM tag
and corresponding amino acid residues 12–465, was cloned intolsevier B.V. All rights reserved.
Table 1
Data collection and reﬁnement statistics
Data collection parameters
Space group P43212
Cell dimensions (Å) a = b = 80.74, c = 178.41
Resolution range (Å) (highest shell) 41.19–2.20 (2.32–2.20)
No. of observations 184 277
No. of unique reﬂections 30 831
Completeness (overall/outer shell) (%) 99.9/100.0
I/rI (overall/outer shell) 13.2/3.4
Rmerge (%) 7.7(54.4)
Reﬁnement parameters
Rwork/Rfree (%) 21.3/25.2
No. of non-hydrogen atoms 3611
No. of water molecules 49
R.m.s deviations from ideal geometry
Bond lengths (Å) 0.008
Bond angles () 1.097
Avg. B-factor 45.0
Ramachandran plot (%)
Favored region 97.6
Allowed region 2.4
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ing. Escherichia coli strain BL21 (DE3) was transformed with the
constructed plasmid. The cells were cultured at 37 C in 1 l of LB
medium containing 100 lg/ml of ampicillin until OD600 reached a
value of 0.7–1.0. The temperature was lowered to 20 C and
expression was induced by an addition of 0.1 mM isopropyl-b-D-
thiogalactoside. After cultivating for 16 h, cells were harvested by
centrifugation. All subsequent handling was at 4 C. The pellets
were resuspended in 50 mM Tris pH 8.0, 150 mM NaCl, 10% glyc-
erol, 2 mM dithiothreitol (DTT), 50 mM imidazole and lysed by
sonication. After centrifugation (30 min at 12,000g), the superna-
tant was applied onto a Ni-NTA column (Qiagen). The target pro-
tein was eluted with 250 mM imidazole and loaded onto a
Resource Q column (GE Healthcare) pre-equilibrated with 50 mM
Tris pH 8.0, 150 mM NaCl, 10% glycerol and 2 mM DTT. Protein
was eluted with a linear NaCl gradient (150–400 mM). Fractions
containing GK were concentrated and loaded on a Superdex 200
column (GE Healthcare) pre-equilibrated with 20 mM Tris pH 8.0,
50 mMNaCl, and 5 mM tris (2-carboxyethyl) phosphine. Wild-type
GK used in the following enzyme assay was prepared similarly.
2.2. Crystallization, data collection, and processing
For crystallization trials, glucose was added to the protein solu-
tion at a ﬁnal concentration of 50 mM. Crystals of E339K GK were
grown at 20 C using the sitting drop vapor diffusion technique.
The best crystals were obtained within two weeks by mixing equal
volumes of protein solution (5 mg/ml) and reservoir solution con-
taining 25% (w/v) PEG3350, 0.1 M HEPES pH 7.3, 0.2 M ammonium
sulfate. For cryo data collection, crystals were sequentially im-
mersed in mother liquors containing an additional 10% and 20%
(v/v) glycerol as cryoprotectant. Data were collected at the Shang-
hai Synchrotron Radiation Facility, using beamline BL17U1
(k = 0.9793 Å) at 100 K with a MX-225 CCD (Marresearch,
Germany). The data were processed with MOSFLM [14] and SCALA
from the CCP4 suite [15]. The structure was solved by molecular
replacement using MOLREP in CCP4 and wild-type GK structure
(PDB entry 1V4S) as the search model. Interactive model building
and reﬁnement were carried out using Coot [16] and PHENIX
[17]. The ﬁnal model was evaluated with MolProbity [18]. The
coordinates and structure factors have been deposited in the Pro-
tein Data Bank under the accession code 3QIC. The data collection
and structure reﬁnement statistics are listed in Table 1. All struc-
ture ﬁgures were created using PyMOL [19].
2.3. Enzyme assay
Both wild-type and E339K mutant GK activities were measured
using glucose-6-phosphate dehydrogenase (G6PDH)/nicotinamide
adenine dinucleotide phosphate (NADP+) coupled enzyme assay
with some modiﬁcation [20]. The assay buffer contained 50 mM
HEPES pH 7.5, 50 mM KCl, 2 mM DTT, 0.1% BSA, 5 mM MgCl2,
0.5 mM NADP+ and 2.5 units/ml G6PDH. To determine glucose
and ATP-related kinetic parameters, glucose was varied (0–
100 mM) with a ﬁxed saturating concentration of 5 mM ATP and
then ATP was also varied (0–5 mM) with a ﬁxed saturating concen-
tration of 100 mM glucose. Assays were performed in a 96-well
microplate with a ﬁnal volume of 100 lL per well at 30 C by mon-
itoring the absorbance at 340 nm. The kinetic parameters were cal-
culated as described previously [20,21].
2.4. Phosphorylation site analysis by mass spectrometry
Protein samples were prepared by SDS–PAGE and sent to Center
of Technical Service for Life Sciences, University of Science andTechnology of China, Hefei, China. Sample processing, data search-
ing and analysis were all performed there.
Data-dependent MS/MS was performed. Electrospray spectra
were acquired on a Thermo-Finnigan LTQ linear quadrupole ion
trap mass spectrometer. The samples were digested by trypsin.
Experimental results for the LTQ data were acquired using a C18
Reversed Phased Capillary Column. The mobile phase consisted
of mobile A (0.1% formic acid in ddH2O) and mobile B (100% aceto-
nitrile). All spectra were obtained in positive ionization mode.
Sample analyses were performed using data-dependent/dynamic
exclusion with a repeat count of one to maximize coverage. All
data ﬁles were searched against the human database.
3. Results
3.1. Overall structure of E339K GK
The X-ray crystal structure of the E339K GK (glucose binding
form) was determined at a resolution of 2.2 Å by molecular
replacement. The crystal belongs to space group P43212 with one
molecule in the asymmetric unit. The reﬁned structure of E339K
GK consists of 453 residues, from Tyr7 to Lys459. The overall struc-
ture of the E339K GK is similar to the active form of wild-type GK
(PDB entry 1V4S) with a root mean square deviation (r.m.s.d.) of
1.1 Å between Ca atoms of the two structures. Superimposing
the mutant GK structure to the wild-type GK structure with only
the large domain reveals a slight movement of the small domain
(Fig. 1A). R.m.s.d. for the large and the small domain between the
two structures is 1.0 and 1.6 Å, respectively. Signiﬁcant differences
are observed around the mutated residue.
The electron density map for K339 and surrounding residues is
shown in Fig. 2A. The E339K mutation was also conﬁrmed by mass
spectrometry (data not shown). Surprisingly, the electron density
map clearly showed extra density around the OG atom of Ser411
(Fig. 2B). It can be modeled very well as a phosphate (PO3) cova-
lently linked to residue Ser411. Mass spectrometry data conﬁrmed
the phosphorylation at Ser411. One phosphate was found in the
peptide from residues 404–414 and was located in Ser411
(Fig. 3). No phosphorylation at Ser411 was found in the wild-type
GK (data not shown).
3.2. Structural comparison of E339K with wild-type GK
In wild-type structure, Glu339 is located in the loop between
helix a9 (residues 331–338) and helix a10 (residues 345–355).
Fig. 2. The quality of electron density. (A) 2mFo  DFc map around mutated residue 339, contoured at 0.8r. (B) Electron density at phosphorylated serine 411. 2mFo  DFc
map (contoured at 1.5r, blue), mFo  DFc omit map (contoured at 5.0r, green).
Fig. 1. Comparison of wild-type and E339K GK structures with superimposition using only the large domain. Wild-type GK complexed with glucose (PDB entry 1V4S, cyan).
E339K GK complexed with glucose (orange). Hydrogen bonds shown as dashes, distances also indicated (Å). Residues with signiﬁcant changes colored, 1V4S in cyan and
E339K in magenta. (A) Overall comparison of wild-type and E339K GK. (B) Conformational variations around residue 339.
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show that Glu339 forms two hydrogen bonds with His416 and
Arg422 (Fig. 1B). The substituted Lys339 would produce unfavor-
able interactions with the residues mentioned above if it adopts
the conformation as Glu339. Instead, Lys339 takes the opposite
orientation and forms a hydrogen bond with the carbonyl oxygen
of Asp344 (Fig. 2A). With the loss of hydrogen bonding, the side
chain of His416 is rotated by nearly 90 and the side chain of
Arg422 is more ﬂoppy in the mutant structure. Also, helix a9 is
shorter as the mutation perturbs the helix formation.
Thr82 is located in the loop (residues 79–84) region linking two
b-sheets (b2 and b3). In the mutant structure, the main chain of
this loop moves notably closer to the large domain (Fig. 1B). The
Ca atom of Thr82 shifts about 3 Å toward the short helix a110(residues 412–416). Ser411 is positioned at the N terminus of helix
a110. Phosphorylation of Ser411 provides a new interaction with
Thr82 (Fig. 1B). The phosphate moiety of SEP411 also interacts
with the short loop (residues 226–230) and forms a hydrogen bond
with the hydroxyl group of Thr228.
4. Discussion
A novel mutation, E339K, was found in a Chinese family by Shen
et al. [13]. According to clinical features and laboratory examina-
tions, the patients were diagnosed with fasting hyperglycemia.
The kinetics analysis showed lower afﬁnity for glucose and ATP,
resulting in the dramatically decreased relative activity of E339K
[13]. To better understand the mechanism of how E339K mutation
Fig. 3. Mass spectrometric analysis of E339K GK. MS/MS spectrum of E339K GK peptide at 1217 Da. This peptide, residues 404–414, contains a phosphorylation site.
Phosphorylated amino acids are shown in the sequence. Peaks labeled using Bioworks Browser 3.3.
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ﬁrst GK mutant crystal structure and showed its structural differ-
ences with wild-type GK. Superimposing the crystal structure of
wild-type GK complexed with glucose and the non-hydrolyzable
ATP analog adenylyl-imidodiphosphate (AMPPNP) (PDB entry
3ID8, unpublished data) with our current structure (Fig. 4A), we
can clearly understand why this mutation causes loss of enzymatic
activity. The structures manifest conformational changes in the
Glu339 loop region as a result of a single mutation. Glu339 estab-
lishes two hydrogen bonds with His416 and Arg422 (Fig. 1B). The
hydrogen bond between Glu339 and His416 is the major stabiliz-
ing force for the correct conformation of His416 in the wild-type
structure. In the mutant structure, the E339K disrupts the hydro-
gen bond between Glu339 and His416. Consequently, His416
adopts another conformation by changing the orientation of itsFig. 4. Comparison of ATP binding pockets for wild-type and E339K GK. Wild-type GK c
with glucose (orange). (A) Diagram of wild-type and E339K GK. (B) Surface view of wildside chain. Therefore, the imidazole ring of His416 would be situ-
ated in close vicinity of the AMPPNP adenine ring based on the
superposition of the E339K structure and 3ID8 (Fig. 4A). The dis-
tance between His416 NE2 and AMPPNP C2 will then only be about
1.5 Å. Apparently, this close contact would hinder the binding of
AMPPNP. The ATP binding will have to take another orientation
in this situation.
We observed phosphorylated Ser411, conﬁrmed by mass spec-
trometric analyses. A direct consequence of the phosphorylation at
Ser411 is the formation of hydrogen bond interaction with Thr82,
which is positioned in the loop (residues 79–84) linking b2 and b3.
This hydrogen bond interaction pulls Thr82 closer to SEP411 and
spatially blocks the entrance of the ATP binding pocket (Fig. 4A).
From the surface view of the two structures (Fig. 4B and C), the
ATP binding pocket has altered considerably in E339K, especiallyomplexed with glucose and AMPPNP (PDB entry 3ID8, cyan). E339K GK complexed
-type GK. (C) Surface view of E339 GK.
Table 2
Kinetic constants of wild-type and E339K GK. The results from three preparations are
recorded. Mean ± S.E. are given. The S0.5 and nH (Hill coefﬁcient) values were obtained
from the Hill equation and Km from the Michaelis–Menten equation [20]. GK
phosphorylating relative activity was normalized relative to the wild-type value.
Relative activity = (GK Kcat/glucose S0.5nH) (2.5/2.5 + ATP Km) [21].
Glucose S0.5
(mmol/L)
nH ATP Km (mmol/
L)
Relative
activity
WT 8.65 ± 0.28 1.75 ± 0.09 0.32 ± 0.06 1.00
E339K 15.44 ± 0.48 1.60 ± 0.05 1.50 ± 0.18 0.20
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‘‘closed door’’ and leave no space for ATP binding. This also corrob-
orates well with the kinetics analysis (Table 2). For the E339K mu-
tant, the glucose S0.5 increased only two folds while the ATP Km
increased ﬁve folds comparing with the wild-type GK.
It has been reported before that serine residues in GK can be
phosphorylated by protein kinase A in vitro [22]. For the ﬁrst time,
our structure showed that Ser411 at the ATP binding site can be
phosphorylated and this phosphorylation has direct consequence
on the ATP binding. Throughout the puriﬁcation and crystallization
processes, the protein was not exposed to any phosphate related
compound. Therefore the formation of this phosphorylated residue
should have occurred inside the cell. We speculate that this is an
autophosphorylation utilizing the ATP in the E. coli. In the E339K
structure, the original ATP binding pocket was blocked, thus the
phosphate group that should have been added to the glucose was
wrongly placed to the hydroxyl group of Ser411. Furthermore,
Ser411 was completely phosphorylated with occupancy 1.0 from
the electron density ﬁtting (Fig. 2B). The strong presence of phos-
phorylated serine in the crystals implies that the phosphorylation
should be stable enough against hydrolysis and persist for a con-
siderably long period. But more data is needed to prove this
hypothesis.
Up to date, several hundred mutations of GK have been found.
But the relationship between the mutation and enzyme activity
is unclear. In addition, there are few reports on the phosphoryla-
tion of GK. Here we present the ﬁrst mutant crystal structure of
GK and also report the ﬁrst structural evidence of the phosphory-
lation of GK. Our structure reveals that the E339K mutation, along
with the phosphorylation of Ser411 at the ATP binding site, induces
the changes of the ATP binding pocket and results in loss of enzy-
matic activity. This provides structural insight into how the E339K
mutation contributes to hyperglycemia. Further studies of Ser411
phosphorylation may add to our understanding of the mechanism
of GK.
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